Canephron® N: what the instructions for use do not tell you?

Every medicine on the pharmaceutical market has its own unpredictable «fate» and life cycle. This publication reflects the most important steps in the pharmacological pathway of Canephron^® N (manufactured by Bionorica, Germany), which has a history of use of more than 80 years. The authors of the publication have analyzed some aspects of the drug’s pharmacodynamics that are currently not covered by the instructions for medical use. All the scientific data obtained very reasonably complement the well-known pharmacological portrait of Canephron^® N and open up prospects for further expansion of its clinical use.

References

1. Market Research Intellect. http://www.marketresearchintellect.com.
2. Thalidomide: medical compound. Britannica. 2025. http://www.britannica.com/science/thalidomide#ref658175.
3. Vargesson N. (2015) Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today, 105(2): 140–156. doi: 10.1002/bdrc.21096.
4. Інструкція для медичного застосування лікарського засобу: ацетилсаліцилова кислота. Ліки контроль. likicontrol.com.ua/%D1%96%D0%BD%D1%81%D1%82%D1%80%D1%83%D0%BA%D1%86%D1%96%D1%8F/?[11519]4.
5. TechTargetet and Informa Tech’s Digital Businesses Combine. Understanding the Pharmaceutical Drug Development Life Cycle. http://www.techtarget.com/pharmalifesciences/news/366606452/Understanding-the-Pharmaceutical-Drug-Development-Life-Cycle.
6. Kunle O.F., Egharevba H.O., Ahmadu P.O. (2012) Standardization of herbal medicines — A review. J. Biodiversity and Conservation, 4(3): 101–112. doi: 10.5897/IJBC11.163.
7. Okigbo R.N., Anuagasi C.L., Amadi J.E. (2009) Advances in selected medicinal and aromatic plants indigenous to Africa. J. Med. Plant. Res., 3(2): 86–95.
8. Verma S., Singh S.P. (2008) Current and future status of herbal medicines. Veterinary World, 1(11): 347–350.
9. Wachtel-Galor S., Benzie I.F.F. (2011) Herbal Medicine: An Introduction to Its History, Usage, Regulation, Current Trends, and Research Needs. In: I.F.F. Benzie, S. Wachtel-Galor (Eds). Herbal Medicine: Biomolecular and Clinical Aspects. 2nd ed. Boca Raton (FL): CRC Press/Taylor & Francis. Chapter 1.
10. Eisenberg D.M., Davis R.B., Ettner S.L. et al. (1998) Trends in alternative medicine use in the United States, 1990–1997: Results of a follow-up national survey. JAMA, 280: 1569–1575.
11. Barnes P.M., Bloom B. (2007) Complementary and alternative medicine use among adults and children: United States. National Health Statistics Reports, 2008 Contract No.: 12.
12. Зупанець І.А. та ін. (2024) Фітонірингові лікарські засоби у сучасній фітотерапії: монографія. Золоті сторінки, Харків, 280 с.
13. Directive 2004/24/EC of the European Parliament and of the Council of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use of 31 March 200. eur-lex.europa.eu/eli/dir/2004/24/oj/eng.
14. Державний реєстр лікарських засобів України. Інформаційний фонд. Канефрон.http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlist?opendocument&query=%CA%E0%ED%E5%F4%F0%EE%ED.
15. Miotla P., Wawrysiuk S., Naber K. et al. (2018) Should We Always Use Antibiotics after Urodynamic Studies in High-Risk Patients? Biomed. Res. Int., 2018: 1607425. doi: 10.1155/2018/1607425.
16. Höller M., Steindl H., Abramov-Sommariva D. et al. (2021) Treatment of Urinary Tract Infections with Canephron® in Germany: A Retrospective Database Analysis. Antibiotics (Basel), 10(6): 685. doi: 10.3390/antibiotics10060685.
17. Naber K.G. (2013) Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia. K.G. Nabe. Research and Reports in Urology, 5: 39–46. doi.org/10.2147%2FRRU.S39288.
18. Kranz J., Schmidt S., Lebert C. et al. (2017) Uncomplicated Bacterial Community-Acquired Urinary Tract Infection in Adults. Dtsch Arztebl Int., 114(50): 866–873. doi: 10.3238/arztebl.2017.0866.
19. Wagenlehner F.M., Abramov-Sommariva D., Höller M. et al. (2018) Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urol Int, 101: 327. http://www.ncbi.nlm.nih.gov/pubmed/30231252.
20. European Association of Urology (EAU) Guidelines for Urological Infections. uroweb.org/guidelines/urological-infections/summary-of-changes/2025.
21. Зупанець І.А., Безугла Н.П., Отрішко І.А., Урсол Г.М. (2023) Сучасні лікарські засоби для фітотерапії: погляд лікаря та фармацевта. Укр. мед. часопис, 6(158): 23–28.
22. Зупанець І.А., Безугла Н.П., Отрішко І.А., Урсол Г.М. (2023) Фітотерапія: лікарські засоби vs БАД. Укр. мед. часопис, 4(156): 26–32.
23. Kardos P., Dinh Q.T., Fuchs K.H. et al. (2020) German Respiratory Society guidelines for diagnosis and treatment of adults suffering from acute, subacute and chronic cough. Respir. Med., 170: 105939. doi: 10.1016/j.rmed.2020.105939.
24. EUR-lex: Access to European Union law. eur-lex.europa.eu/eli/dir/2001/83/oj/eng.
25. European Association of Urology (EAU) Guidelines for Urological Infections. uroweb.org/guidelines/urological-infections/summary-of-changes/2024.
26. Chernykh V.V., Zupanets I.A., Shebeko S.K. (2022) Effect of phytoneering remedy BNO 2103 on the course of experimental exudative inflammation caused by different phlogogens. Запорізький медичний журнал, 1(130): 84–90. doi.org/10.14739/ 2310-1210.2022.1.237675.
27. Shebeko S.K., Chernykh V.V., Zupanets K.O. (2020) Nephroprotective Effect of the Herbal Composition BNO 2103 in Rats with Renal Failure. Scientia Pharmaceutica, 88(4): 47. doi: 10.3390/scipharm88040047.
28. Шебеко С.К., Зупанець І.А., Пропіснова В.В., Шаламай А.С. (2018) Експериментальне дослідження ефективності Глюкваміну при тубулярному ураженні нирок. Укр. біофармац. журн., 2: 56–60. doi: 10.24959/ubphj.18.170.
29. Milosevic M., Magnutzki A., Braun T. et al. (2025) Anti-inflammatory and cytoprotective polypharmacology of Canephron N reveals targeting of the IKK-NF-κB and p38-MK2-RIPK1 axes. Biomed. Pharmacother., 182: 117747. doi: 10.1016/j.biopha.2024.117747.